News Release

Printer Friendly Version View printer-friendly version
« Back
PRA Health Sciences to Report Third Quarter 2015 Results

RALEIGH, N.C., Oct. 16, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2015 results after the market closes on Monday, November 2, 2015. The Company will also host a conference call on Tuesday, November 3, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 63585117. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 63585117.

A live audio broadcast of the teleconference will also be available on the investor relations section of the PRA Health Sciences website, Following the teleconference, an audio playback of the call will be available at the same website.


PRA Health Sciences is one of the world's leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.

Investor Inquiries:

Media Inquiries: Christine Rogers, Manager – Public Relations, Corporate Communications
Email:  Phone: +919.786.8463

Primary Logo

PRA Health Sciences, Inc.